Rallybio Gets $50M Termination Fee, Shares Surge

Rallybio Corp's shares rose about 47% on May 4, 2026 after announcing a $50 million termination fee from a collapsed merger.
The merger with Candid Therapeutics was terminated on May 3, 2026 after Candid signed an alternative agreement with UCB S.A.
Under the original March 1, 2026 agreement, Rallybio is entitled to the $50 million parent termination fee and expense reimbursement.
Rallybio will withdraw its Form S‑4 registration statement filed March 17, 2026 and amended April 24, 2026.